{
  "docId": "019de071-7055-71be-8e36-ff3241c1e380",
  "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2",
  "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides",
  "authorId": "renovorx",
  "authorName": "RenovoRx",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 12,
  "pageCount": 29,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/12",
  "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380",
  "deckJsonHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380.json",
  "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Gemcitabine: IV (systemic) gemcitabine marketed in US since 1996; Established as part of current standard of care; Potent anti-tumor agent; Pre-clinical studies: inhibits 80-100% of tumor growth; Limitations include poor tumor tissue penetration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f3dbb1a-050c-4525-898c-43bae7febf86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "RenovoGem (Intra-arterial Gemcitabine + RenovoCath delivery): Intra-arterial gemcitabine for treatment of solid tumors; FDA Orphan Drug Designation; Phase 1/2 data showed median survival of 27.9 months vs 12-15 months; Ongoing Phase 3 trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d99f01d5-6475-417b-b9c3-f664c4e096dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "We Employ De-risked Small Molecule Chemotherapy Drugs First Drug Candidate: Intra-Arterial Gemcitabine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99851b5e-b9c3-437d-a2d8-898fdb756049",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 8,
      "beatId": "bc74b34e-10ae-4e2c-abba-8a2b7368ea8b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 8-13 present the solution and product demo",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7",
      "evidence": "Slides 4 and 28 present the executive summary and investment highlights",
      "position": 1,
      "objective": "Present the investment highlights and ask",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}